Vanguard Portfolio Management’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$374M Sell
6,569,792
-23,759
-0.4% -$1.38M 0.02% 814
2026
Q2
$383M Buy
6,593,551
+314,006
+5% +$17.1M 0.02% 840
2026
Q1
$365M Buy
+6,279,545
New +$341M 0.02% 795

Other funds holding PCVX

Vanguard Portfolio Management's PCVX Position: Q3 2026 in Review

Vanguard Portfolio Management reduced its Vaxcyte (PCVX) stake by 0.36% in Q3 2026, selling an estimated $1.38M and leaving 6,569,792 shares worth $374M. The position accounts for 0.02% of the portfolio, ranked #814.

Vanguard Portfolio Management first reported a position in PCVX in Q1 2026 and has held it in 3 quarters since. The position peaked at $383M in Q2 2026. 272 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Vanguard Portfolio Management held 6,569,792 shares of Vaxcyte worth $374M as of Q3 2026.
  • Vanguard Portfolio Management sold 23,759 Vaxcyte shares in Q3 2026, an estimated $1.38M.
  • Vaxcyte made up 0.02% of Vanguard Portfolio Management's portfolio in Q3 2026, its #814 holding.
  • Vanguard Portfolio Management first reported a position in Vaxcyte in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Portfolio Management's Vaxcyte position peaked at $383M in Q2 2026.
  • 272 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.